Brazil Scraps Covaxin Emergency Use Application Amid Political Row: Report

The Brazilian health regulator's decision comes after the vaccine maker informed the South American country about the termination of its pact with its partners in the country.

After suspending the proposed clinical trials of Bharat Bioetch's Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian firm for the vaccine. The Brazilian health regulator's decision comes after the vaccine maker informed the South American country about the termination of its pact with its partners in the country. According to a statement issued by the National Health Surveillance Agency of Brazil, Anvisa, its Collegiate Board on Saturday unanimously decided "to close the process that dealt with the temporary authorization of emergency use, on an experimental basis, of the Covaxin vaccine". Earlier Anvisa had suspended the clinical studies of Bharat Biotech's COVID-19 vaccine Covaxin in Brazil following the termination of the companys agreement with its partners there.